LAVA Therapeutics GAAP EPS of -$0.32 misses by $0.06

* LAVA Therapeutics press release [https://seekingalpha.com/pr/20200312-lava-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:LVTX [https://seekingalpha.com/symbol/LVTX]): Q2 GAAP EPS of -$0.32 misses by $0.06.
* LAVA had cash, cash equivalents, and short-term investments of $56.2 million, compared to cash, cash equivalents, and short-term investments of $76.6 million as of December 31, 2024.

MORE ON LAVA THERAPEUTICS

* XOMA Royalty to acquire cancer drug developer LAVA Therapeutics [https://seekingalpha.com/news/4477180-lava-therapeutics-stock-gains-ma-deal-with-xoma]
* Seeking Alpha’s Quant Rating on LAVA Therapeutics [https://seekingalpha.com/symbol/LVTX/ratings/quant-ratings]
* Historical earnings data for LAVA Therapeutics [https://seekingalpha.com/symbol/LVTX/earnings]
* Financial information for LAVA Therapeutics [https://seekingalpha.com/symbol/LVTX/income-statement]